A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.

about

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.

Item

http://www.wikidata.org/entity/Q42132657

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.

@en

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.

@nl

type

Item

label

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.

@en

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.

@nl

prefLabel

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.

@en

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.

@nl

P1476

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.

@en

P2093

Chun Wang

http://www.w3.org/2001/XMLSchema#string

Daolin Wei

http://www.w3.org/2001/XMLSchema#string

Haitao Bai

http://www.w3.org/2001/XMLSchema#string

Qi Cai

http://www.w3.org/2001/XMLSchema#string

Yanrong Gao

http://www.w3.org/2001/XMLSchema#string

Yin Tong

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

International staging system for multiple myeloma.

International uniform response criteria for multiple myeloma.

P304

70168-70174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12162

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27659525

http://www.w3.org/2001/XMLSchema#string

P932

5342543

http://www.w3.org/2001/XMLSchema#string